Skip to main content

Market Overview

Have You Heard About This Generic EpiPen Maker?

Have You Heard About This Generic EpiPen Maker?

Mylan NV (NASDAQ: MYL) is the latest pharmaceutical company to come under government scrutiny.

Mylan is the maker of a device that provides epinephrine in the event of anaphylaxis — also known as the EpiPen. According to Fortune, Mylan built the EpiPen from a "weakening enterprise" in 2007 to become a "pile of money" segment that reportedly accounts for 50 percent of the company's total operating profits.

However, since 2007 the company boosted the price of the EpiPen by 400 percent, which actually looks "meager" compared to the "whopping" 671 percent salary increase Mylan handed its CEO Heather Bresch over the same time period.

Charles Grassley (R-Iowa), chairman of the judiciary committee, reached out to both Bresh and the company asking them to explain the justification behind a 400 percent increase in its product.

Related Link: Teva Says Its Generic EpiPen Will Be "Significantly Delayed"

Generic EpiPen Maker

Antares Pharma Inc (NASDAQ: ATRS), a small-cap specialty pharmaceutical company, saw its shares jump 12 percent on Tuesday. The company supplies Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) with its own generic version of the EpiPen that has yet to be approved for use by the U.S. Federal Drug Administration (FDA).

Antares said in a presentation in early January that it has received questions from the FDA as part of a standard ongoing active review of the application for its generic version of EpiPen. The company also said in the same presentation that Teva expects approval of an AB rated (generically equivalent rated) product "at the earliest in 2H16."

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!


Related Articles (MYL + ATRS)

View Comments and Join the Discussion!

Posted-In: Antares PharmaBiotech News Health Care Top Stories Media Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at